Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

Exclusion Criteria

• •Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• •Concurrently participating in another clinical study, at any time during the study period (up to the Month 12/13 visit), in which the subject has been or will be exposed to an investigational or a non-investigational product.
• •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
• •Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after each dose of vaccine. Administration of routine vaccines up to 8 days before the first dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window.
• •A woman planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the study period and up to two months after the last vaccine dose.
• •Pregnant or breastfeeding women.
• •Previous vaccination against HPV, or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period.
• •previous administration of components of the investigational vaccine
• •Administration of a pre-school booster of diphtheria, tetanus, pertussis vaccine within the previous five years.
• •Administration of a diphtheria-tetanus booster or tetanus-diphteria-acellular pertussis (Tdap) vaccine within the previous five years.
• •Previous vaccination against Neisseria meningitidis.
• •Hypersensitivity to latex.
• •Cancer or autoimmune disease under treatment.
• •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine or following any other tetanus toxoid, diphtheria toxoid or pertussis-containing vaccine.
• •History of encephalopathy within seven days of administration of a previous dose of pertussis vaccine that is not attributable to another identifiable cause.
• •Progressive neurologic disorder, uncontrolled epilepsy or progressive encephalopathy.
• •Temperature of \>= 105°F within 48 hours of receipt of a prior dose of diphteria- tetanu-pertussis (DTP) vaccine, not due to another identifiable cause.
• •Collapse or shock-like state within 48 hours of receipt of a prior dose of DTP vaccine.
• •Seizures with or without fever within three days of a prior dose of DTP vaccine.
• •Severe Arthus-type hypersensitivity reactions following a prior dose of tetanus toxoid within the previous 10 years.
• •Previous history of Guillain-Barré syndrome.
• •Any confirmed or suspected immunosuppressive or immunodeficient condition
• •Acute disease at the time of enrolment. All vaccines can be administered to persons with a minor illness
• •Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.